Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients

Hamid Hasson1a, Priscilla Biswas1b, Laura Gall1a, Samuele E. Burastero1c, Anna Danise1a, Alba Bigoloni1a, Elisabetta Carini1a, Massimo Locatelli3, Andrea Vecchi1b, Adriano Lazzarin2b, Antonella Castagna1a

1San Raffaele Scientific Institute, Milan, Italy; 2Università Vita-Salute, Milano, Italia e Istituto Scientifico San Raffaele, Milano, Italia; 3Laboraf Diagnostica e Ricerca San Raffaele S.p.A.; 4Clinic of Infectious Diseases; 5Laboratory of Clinical Immunology; 6Unit of Leukocyte Biology

Enfuvirtide (ENF) is the first HIV-1 entry inhibitor used in clinical practice and is currently administered via the subcutaneous route. We here evaluated whether ENF administration leads to a change in humoral parameters, including IgE, possibly related to ENF-associated injection site reactions (ISRs). A 24-week prospective study was conducted in multidrug resistant patients enrolled in the ENF Early Access Program characterized by CD4 counts <100 cells/microlitre and no other active antiretroviral drug. Licensed commercial laboratory assays were used to measure the parameters considered in this study. Results are reported as medians (interquartiles IQR). Statistical analyses were performed using Wilcoxon sign rank, Wilcoxon rank sum and Kruskall Wallis tests. Total IgM, IgA and IgG did not change significantly throughout the study. Conversely, a significant increase in IgE was observed in all patients, in those with normal as well as in those with altered IgE at baseline (BL). ISRs such as induration and number of nodules were more frequent in patients with altered BL IgE. IgE increased significantly in all patients, regardless of the different stratifications in their BL CD4 counts. Of note, the ENF-induced increase in CD4 occurred significantly in all patients, independently of their BL IgE levels. The immunological response associated with ENF treatment is accompanied by a selective increase in IgE levels. Determination of IgE could be used in the monitoring ISRs associated with ENF.

KEY WORDS: Enfuvirtide (ENF), IgE, CD4, Injection site reactions (ISRs), Immunological response

INTRODUCTION

Enfuvirtide (ENF) is the first of a new class of drugs, the entry inhibitors, to have joined the therapeutic armamentarium against HIV (Castagna et al., 2005; Moore and Doms, 2003). It is a synthetic peptide which inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120 (Asboe, 2004; Cervia and Smith, 2003; Liu et al., 2005; Matthews et al., 2004). Large phase III clinical trials have shown that ENF plus an optimized background (OB) of other antiretroviral drugs offers more benefit than OB alone in terms of gain in CD4 cell counts and reduction in HIV viraemia (Lalezari et al., 2003; Lazzarin et al., 2003). Of interest, cross-reactive gp41 anti-